Book contents
- Decriminalizing Mental Illness
- Decriminalizing Mental Illness
- Copyright page
- Contents
- Contributors
- Part I Introduction/Description of the Problem
- Part II Solutions
- Part III Psychopharmacological Treatment Considerations
- Chapter 18 Dopamine Antagonist Antipsychotics in Diverted Forensic Populations
- Chapter 19 Monitoring and Improving Antipsychotic Adherence in Outpatient Forensic Diversion Programs
- Chapter 20 Pharmacological Treatment of Violence in Schizophrenia
- Part IV Nonpsychopharmacological Treatment Considerations
- Part V Criminal Justice and Social Considerations
- Index
- References
Chapter 18 - Dopamine Antagonist Antipsychotics in Diverted Forensic Populations
from Part III - Psychopharmacological Treatment Considerations
Published online by Cambridge University Press: 19 October 2021
Book contents
- Decriminalizing Mental Illness
- Decriminalizing Mental Illness
- Copyright page
- Contents
- Contributors
- Part I Introduction/Description of the Problem
- Part II Solutions
- Part III Psychopharmacological Treatment Considerations
- Chapter 18 Dopamine Antagonist Antipsychotics in Diverted Forensic Populations
- Chapter 19 Monitoring and Improving Antipsychotic Adherence in Outpatient Forensic Diversion Programs
- Chapter 20 Pharmacological Treatment of Violence in Schizophrenia
- Part IV Nonpsychopharmacological Treatment Considerations
- Part V Criminal Justice and Social Considerations
- Index
- References
Summary
In community settings, the principle barriers to independent living, stable relationships, and gainful employment arise from the negative and cognitive symptom domains of schizophrenia spectrum disorders., In contrast, the positive symptoms of psychosis often are the gateway (e.g. via persecutory delusion associated with anger) to arrest and criminalization for the mentally ill. Since the clinical discovery of chlorpromazine in 1952, dopamine antagonism in the mesolimbic dopamine circuit has been central to treating the positive symptoms of psychosis. The hyperactivity of the mesolimbic circuit and the normalizing effects of the dopamine antagonist antipsychotics are illustrated in Figure 18.1.
- Type
- Chapter
- Information
- Decriminalizing Mental Illness , pp. 191 - 199Publisher: Cambridge University PressPrint publication year: 2021
References
Grove, TB, Tso, IF, Chun, J, et al. Negative affect predicts social functioning across schizophrenia and bipolar disorder: findings from an integrated data analysis. Psychiatry Res. 2016; 243: 198–206.Google Scholar
Kaneko, K. Negative symptoms and cognitive impairments in schizophrenia: two key symptoms negatively influencing social functioning. Yonago Acta Med. 2018; 61(2): 91–102.Google Scholar
Ullrich, S, Keers, R, Coid, JW. Delusions, anger, and serious violence: new findings from the MacArthur violence risk assessment study. Schizophr Bull. 2014; 40(5): 1174–1181.Google Scholar
Fazel, S, Zetterqvist, J, Larsson, H, Langstrom, N, Lichtenstein, P. Antipsychotics, mood stabilisers, and risk of violent crime. Lancet. 2014; 384(9949): 1206–1214.Google Scholar
Urs, NM, Peterson, SM, Caron, MG. New concepts in dopamine D2 receptor biased signaling and implications for schizophrenia therapy. Biol Psychiatry. 2017; 81(1): 78–85.Google Scholar
Howes, OD, McCutcheon, R, Owen, MJ, Murray, RM. The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry. 2017; 81(1): 9–20.Google Scholar
Rotter, M, Carr, WA. Targeting criminal recidivism in mentally ill offenders: structured clinical approaches. Community Ment Health J. 2011; 47(6): 723–726.Google Scholar
Lopez-Munoz, F, Alamo, C, Cuenca, E, et al. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005; 17(3): 113–135.Google Scholar
Melkersson, K, Lewitt, M, Hall, K. Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. Neuro Endocrinol Lett. 2015; 36(5): 465–480.Google Scholar
Crilly, J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007; 18(1): 39–60.Google Scholar
Shen, WW. A history of antipsychotic drug development. Compr Psychiatry. 1999; 40(6): 407–414.Google Scholar
Grace, AA. The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. J Neural Transm Suppl. 1992; 36: 91–131.Google Scholar
Miyamoto, S, Duncan, GE, Marx, CE, Lieberman, JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005; 10(1): 79–104.Google Scholar
Howes, O, McCutcheon, R, Stone, J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015; 29(2): 97–115.Google Scholar
Veerman, SR, Schulte, PF, de Haan, L. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. Pharmacopsychiatry 2014; 47(4–5): 121–130.Google Scholar
Howes, OD, McCutcheon, R, Agid, O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017; 174(3): 216–229.Google Scholar
Stroup, TS, Gerhard, T, Crystal, S, Huang, C, Olfson, M. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry. 2016; 173(2): 166–173.Google Scholar
Yoshimura, B, Yada, Y, So, R, Takaki, M, Yamada, N. The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res. 2017; 250: 65–70.Google Scholar
Kerwin, R. When should clozapine be initiated in schizophrenia?: some arguments for and against earlier use of clozapine. CNS Drugs. 2007; 21(4): 267–278.Google Scholar
Doyle, R, Behan, C, O’Keeffe, D, et al. Clozapine use in a cohort of first-episode psychosis. J Clin Psychopharmacol. 2017; 37(5): 512–517.Google Scholar
Galling, B, Roldan, A, Hagi, K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017; 16(1): 77–89.Google Scholar
Stahl, SM, Morrissette, DA, Cummings, M, et al. California state hospital violence assessment and treatment (Cal-VAT) guideline. CNS Spectr. 2014; 19(5): 449–465.Google Scholar
Fond, G, Boyer, L, Favez, M, et al. Medication and aggressiveness in real-world schizophrenia: results from the FACE-SZ dataset. Psychopharmacology. 2016; 233(4): 571–578.Google Scholar
Garriga, M, Pacchiarotti, I, Kasper, S, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016; 17(2): 86–128.Google Scholar
Mossaheb, N, Kaufmann, RM. Role of aripiprazole in treatment-resistant schizophrenia. Neuropsychiatr Dis Treat. 2012; 8: 235–244.Google Scholar
Veerman, SRT, Schulte, PFJ, de Haan, L. Treatment for negative symptoms in schizophrenia: a comprehensive review. Drugs. 2017; 77(13): 1423–1459.Google Scholar
Stahl, SM. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr. 2017; 22(5): 375–384.Google Scholar
Wulff, S, Pinborg, LH, Svarer, C, et al. Striatal D(2/3) binding potential values in drug-naive first-episode schizophrenia patients correlate with treatment outcome. Schizophr Bull. 2015; 41(5): 1143–1152.Google Scholar
Urban, AE, Cubala, WJ. Therapeutic drug monitoring of atypical antipsychotics. Psychiatr Pol. 2017; 51(6): 1059–1077.Google Scholar
Fan, J, de Lannoy, IA. Pharmacokinetics. Biochem Pharmacol. 2014; 87(1): 93–120.CrossRefGoogle ScholarPubMed
Meyer, JM, Cummings, MA, Proctor, G, Stahl, SM. Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am. 2016; 39(4): 541–556.Google Scholar
Dahl, SG. Plasma level monitoring of antipsychotic drugs: clinical utility. Clin Pharmacokinet. 1986; 11(1): 36–61.Google Scholar
Tharani, AJ, Farooq, S, Saleem, F, Naveed, A. Compliance to antipsychotic medication: a challenge for client, family and health care providers. J Pak Med Assoc. 2013; 63(4): 516–518.Google Scholar
Pilkinton, PD, Pilkinton, JC. Prescribing in prison: minimizing psychotropic drug diversion in correctional practice. J Correct Health Care. 2014; 20(2): 95–104.Google Scholar
Marcus, SC, Zummo, J, Pettit, AR, Stoddard, J, Doshi, JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015; 21(9): 754–768.Google Scholar
McGuire, AB, Bond, GR. Critical elements of the crisis intervention team model of jail diversion: an expert survey. Behav Sci Law. 2011; 29(1): 81–94.Google Scholar
Mohr, P, Knytl, P, Vorackova, V, Bravermanova, A, Melicher, T. Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients. Int J Clin Pract. 2017; 71(9): e12997.Google Scholar
Taipale, H, Mittendorfer-Rutz, E, Alexanderson, K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2017; 197: 274–280.Google Scholar
Iyer, S, Banks, N, Roy, MA, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives. Can J Psychiatry. 2013; 58(5 Suppl 1): 23s–29s.Google Scholar
Siragusa, S, Saadabadi, A. Fluphenazine. In: StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2018.Google Scholar
Quraishi, S, David, A. Depot haloperidol decanoate for schizophrenia. Cochrane Database Syst Rev. 2000; 1999(2): CD001361.Google Scholar
Park, EJ, Amatya, S, Kim, MS, et al. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res. 2013; 36(6): 651–659.Google Scholar
Citrome, L. Sustained-release risperidone via subcutaneous injection: a systematic review of RBP-7000 (PERSERIS™) for the treatment of schizophrenia. Clin Schizophr Relat Psychoses. 2018; 12(3): 130–141.Google Scholar